Related Experiment Video
Updated: Aug 9, 2026
11:29
Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma
Published on: January 22, 2022
Salvage cytoreductive surgery for recurrent endometrial cancer
Robert E Bristow1, Antonio Santillan, Marianna L Zahurak
1The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA. rbristo@jhmi.edu
Gynecologic Oncology
|April 25, 2006
Summary
Salvage cytoreductive surgery significantly improves survival for recurrent endometrial cancer patients. Achieving complete tumor removal offers the best outcomes, highlighting surgery
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
- Cancer Recurrence
Background:
- Endometrial cancer recurrence presents a significant clinical challenge.
- Identifying prognostic factors is crucial for managing recurrent disease.
Purpose of the Study:
- To evaluate the survival impact of salvage cytoreductive surgery in recurrent endometrial cancer.
- To identify other prognostic variables affecting survival after recurrence.
Main Methods:
- Retrospective analysis of 61 patients with recurrent endometrial cancer (7/1/97-6/30/05).
- Kaplan-Meier survival estimates and univariate/multivariate regression analyses were performed.
- Data abstracted included demographics, pathology, and clinical details.
Main Results:
- Median survival was 28.0 months with salvage surgery vs. 13.0 months without (P < 0.0001).
- Complete cytoreduction (no gross residual) resulted in 39.0 months median survival vs. 13.5 months with residual disease (P = 0.0005).
- Salvage surgery and residual disease status were independent predictors of survival.
Conclusions:
- Complete salvage cytoreductive surgery is associated with prolonged survival in recurrent endometrial cancer.
- Further research is needed to establish optimal surgical indications and patient selection criteria.
